AG
PRVB

Advisor Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Advisor Group’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$484K Sell
32,450
-84,671
-72% -$754K ﹤0.01% 1693
2019
Q3 		$799K Buy
+117,121
New +$1.18M 0.01% 1292

Other funds holding PRVB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Advisor Group's PRVB Position: Q4 2019 in Review

Advisor Group reduced its Provention Bio, Inc. Common Stock (PRVB) stake by 72% in Q4 2019, selling an estimated $754K and leaving 32,450 shares worth $484K. The position accounts for ﹤0.01% of the portfolio, ranked #1693.

Advisor Group first reported a position in PRVB in Q3 2019 and has held it in 2 quarters since. The position peaked at $799K in Q3 2019. 60 funds tracked by Wall St. Rank hold PRVB as of Q4 2019.

  • Advisor Group held 32,450 shares of Provention Bio, Inc. Common Stock worth $484K as of Q4 2019.
  • Advisor Group sold 84,671 Provention Bio, Inc. Common Stock shares in Q4 2019, an estimated $754K.
  • Provention Bio, Inc. Common Stock made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #1693 holding.
  • Advisor Group first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and has held it in 2 quarters since.
  • Advisor Group's Provention Bio, Inc. Common Stock position peaked at $799K in Q3 2019.
  • 60 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.